Anzeige
Erschienen in:
07.10.2017 | Original Article
Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity
Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2018
Einloggen, um Zugang zu erhaltenAbstract
Aim
We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection.
Methods
The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab—0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab—0.0625 mg/0.025 ml).
Results
Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 ± 65 and 97 ± 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 ± 1.7 vs 3.66 ± 2.46 days, respectively, p = 0.03).
Conclusions
The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.